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Background: There are racial disparities in the use of alcohol and other drug (AOD) treatment services in South
Africa but little is known about the factors contributing to these disparities. This study aimed to redress this gap
through identifying differences in barriers to AOD treatment use among Black African and Coloured persons from
Cape Town, South Africa. The Behavioral Model of Health Services Utilization was used as an analytic framework.
Methods: A case-control design was used to compare 434 individuals with AOD problems who had accessed
treatment with 555 controls who had not accessed treatment on a range of variables. Logistic regression
procedures were employed to examine the unique profile of variables associated with treatment utilization for
Black African and Coloured participants.
Results: After controlling for the influence of treatment need and predisposing factors on treatment use, several
barriers to treatment were identified. Greater awareness of treatment options and fewer geographic access and
affordability barriers were strongly associated with an increased likelihood of AOD treatment use for both race
groups. However, Black African persons were more vulnerable to the effects of awareness and geographic access
barriers on treatment use. Stigma consciousness was only associated with AOD treatment utilization for Coloured
participants.
Conclusion: Differences in barriers to AOD treatment use were found among Black African and Coloured South
Africans. Targeted interventions that address the unique profile of barriers experienced by each race group are
needed to improve AOD treatment use by these underserved groups. Several strategies for improving the
likelihood of treatment entry are suggested.
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Findings from national epidemiological research point to
high rates of untreated alcohol and other drug (AOD)
use disorders in South Africa [1]. This is cause for concern
as AOD use poses a significant threat to public health in
the country. These problems are particularly prevalent in
the Western Cape province, with a recent representative
survey reporting significantly higher rates for AOD use
disorders (20.3%) in this province compared to the na-
tional average of 13.3% [1]. Cape Town, the capital of the
Western Cape, is particularly affected by AOD-related
problems with this city reporting the highest proportion ofCorrespondence: bmyers@mrc.ac.za
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reproduction in any medium, provided the oralcohol and drug positive arrestees [2] and emergency
room patients [3] compared to other major cities in the
country. Taken together, these findings highlight the need
for accessible AOD treatment services in Cape Town.
Despite the demand for AOD treatment in this region,
access to treatment is limited in South Africa [4]. While
the limited availability of AOD services restricts access
to treatment for all South Africans, treatment is relative-
ly more difficult to access for people from Black African
and Coloured (that is people of mixed race ancestry who
form a unique cultural group) communities disadvan-
taged during the course of apartheid who remain under-
represented in AOD treatment facilities [5]. These racial
disparities in access to treatment are probably an artifact
of the apartheid system of governance. During apartheid,
race was a major determinant of access to health andis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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having more access to public services than Coloured or
Black African South Africans [6,7]. These disparities
arose from the legislated geographic segregation of race
groups and the distribution of resources along racial
lines. This geographical apartheid forced Black African
and Coloured South Africans to live in township areas
with limited infrastructure that were located consider-
able distances from the well-resourced urban areas re-
served for the use of White South Africans [6].
Despite 18 years of democracy, South Africa is still
grappling with the legacy of apartheid and the challenges
of promoting equitable access to public services for all
racially-defined social groups. Race remains an import-
ant marker of socio-economic advantage in the country
which impacts on the extent to which individuals are
able to access services [7]. Poor Black African and
Coloured persons continue to experience the most diffi-
culty in accessing health services (including AOD ser-
vices) relative to other groups [6,8]. Only about 16% of
South Africans are members of private health insurance
schemes (known as medical schemes) and use health
services in the private health sector. The remaining 84%
of the population, disproportionately represented by
poor Black African and Coloured South Africans, are
mainly dependent on the overburdened and under-
resourced public services sector for access to health care
(although some pay out-of-pocket for basic primary care
services in the private sector) [8]. Racial disparities in ac-
cess to AOD treatment are likely to be entrenched by
the limited availability of free AOD treatment services in
the public service sector. For example in the Western
Cape province, which arguably is among the better
resourced provinces in terms of access to AOD treat-
ment services [4,5], there are only three AOD outpatient
services and three inpatient facilities available in the
public service sector that offer free treatment services.
The remainder of the AOD inpatient treatment facilities
in the province are either private non-profit facilities
that offer reduced-cost services but still charge co-
payment fees or private for-profit facilities that cater for
the proportion of the population with access to medical
insurance and charge high fees. Apart from outpatient
services offered in the public sector, there are also out-
patient services provided by private non-profit treatment
providers. Although these agencies provide low-cost ser-
vices, some do require clients to make a financial contri-
bution towards each appointment. While these AOD
services are among the least expensive, these are often
unaffordable to poor South Africans, especially when
coupled with the costs of travelling to these services.
However, there has been no research on affordability
barriers and other factors that may contribute to racial
disparities in AOD treatment use. This is worrisome asunderstanding how barriers and facilitators to AOD treat-
ment entry vary across racial groups is a prerequisite for
developing targeted interventions aimed at expanding
AOD treatment coverage for underserved groups. This
study aimed to redress this gap by identifying differences
in barriers and facilitators to AOD treatment use among
Black African and Coloured persons from Cape Town,
South Africa.
The theoretical basis for this study was the Behavioral
Model of Health Services Utilization (BHSU) [9]. This
model was selected because it has been used extensively
to examine behavioral health services use, including the
use of AOD services [9-11] and also because it explicitly
recognises that need for care and psychological and so-
cial factors influence access to treatment; factors that are
often downplayed in other models of access [11]. This
model adopts a systems approach that integrates a range
of individual, contextual and provider variables associ-
ated with health services use into a single framework. It
allows researchers to examine why individuals use health
services, measure equitable access to health services,
and guide policy development concerning service use.
The model is thought to both predict and explain health
service utilisation. Specifically, the BHSU suggests that
health service use is a function of the separate and com-
bined influence of predisposing characteristics, factors
that enable or restrict health service use, and need vari-
ables. Predisposing characteristics (such as demographic
and attitudinal-belief variables) exist within a person
prior to the onset of a specific health need and predis-
pose a person to use services. Enabling factors represent
the person’s actual ability to obtain health services and
include affordability factors, geographic accessibility and
awareness of services, as well as psychological function-
ing. Service need variables reflect internal and external
perceptions that health problems are severe enough to
warrant the use of services [9,10].Methods
Study design
This study used a case-control design to compare cases
and controls on a range of variables thought to be asso-
ciated with AOD treatment utilization. Cases were de-
fined as persons from disadvantaged communities with
AOD problems who reported AOD treatment use in the
12 months preceding the study. Controls were defined as
persons from disadvantaged communities who had not
used AOD treatment prior to this study, despite having
AOD problems that required treatment. To control for se-
lection bias, frequency matching techniques were used to
match cases and controls on gender and race dimensions.
To limit recall bias, we used time-line follow back (TLFB)
procedures to collect retrospective data [12].
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Convenience samples of Black African and Coloured peo-
ple were recruited from treatment programmes and com-
munities using snowball sampling techniques.
Recruitment of cases
Cases were identified at AOD treatment facilities in Cape
Town, which served as starting points for sampling. To be
selected for inclusion in the study, potential cases had to
be at least 18 years old, self-identify as Black African or
Coloured, earn less than ZAR 2500 per month (at the time
of the study 1 USD = ZAR 9), have received treatment for
AOD problems, and provide informed consent to par-
ticipate in the study. Of the 440 persons screened for po-
tential eligibility, all met the inclusion criteria. Having
established eligibility, informed consent was obtained from
potential cases to administer a questionnaire on access to
treatment. As only six potential cases refused to partici-
pate in the study, the final sample comprised 434 cases.
Fieldworkers then contacted these recruits to arrange a
date and time for completion of the interviewer-
administered questionnaire which took about 90 minutes
to complete. Fieldworkers provided participants with re-
freshments, feedback, and referrals to services where
requested.
Recruitment of controls
Controls were recruited by a team of experienced field-
workers. To ensure controls represented the population
of persons with AOD problems in disadvantaged com-
munities, subjects were recruited from a range of these
communities. Two residential areas from each of the six
sub-structures of the Cape Town metropole were se-
lected as key focus areas for sampling. To be selected as
an area for sampling, the community had to consistently
appear in the South African Community Epidemiology
Network on Drug Use’s list of top ten residential areas
for AOD problems [5], have been classified as a “Black
African” or “Coloured” residential area under the apart-
heid regime, have high levels of health and social prob-
lems (defined as having a high prevalence of infectious
diseases such as HIV and tuberculosis and a high preva-
lence of crime and violence), and be a low-income area.
Fieldworkers entered these communities by contacting
organisations, leaders, and individuals with known inter-
ests in the AOD field and asking them to identify poten-
tial recruits to act as starting points for snowball
sampling. Fieldworkers then screened these potential re-
cruits for eligibility. To be selected as a control, potential
recruits had to be at least 18 years old, self-identify as
Black African or Coloured, earn less than ZAR2500 per
month, have untreated AOD problems in need of treat-
ment (assessed using the Texas Christian University
(TCU) Drug Screen [13]), and provide informed consentto participate in the study. Of the 559 potential recruits
screened, only four did not meet the study’s eligibility
criteria. An overall response rate of 98.3% was obtained
(N = 555). For eligible participants, fieldworkers obtained
consent to administer a questionnaire on access to treat-
ment which took approximately 90 minutes to complete.
Fieldworkers provided participants with refreshments,
feedback, and referrals to AOD services where requested.
Ethical approval for this study was granted by the Ethics
Review Board of the Faculty of Humanities at the Univer-
sity of Cape Town.
Measures
TCU drug screen
The TCU Drug Screen-II [13] was used to screen poten-
tial controls for drug use severity and dependence. This
screener has been used with treatment-seeking popula-
tions and community samples to screen for drug use se-
verity and dependence [13]. The first nine items of the
TCUDS are used to compute a continuous composite
score that measures drug use severity [14]. Composite
scores range from 0 to 9, with a composite score of three
or more indicating relatively severe drug-related prob-
lems that correspond to a DSM-IV-TR drug dependence
diagnosis [15] and indicating an objective need for treat-
ment. The scale's overall reliability is good (α = .89) [13]
and has good test-retest reliability (r = .97) [14]. This
study obtained a Cronbach coefficient alpha of .88 for
the scale. In addition, all controls scored above the cut-
off point of 3, indicating an objective need for treatment.
Measures contained in the access to treatment questionnaire
This questionnaire, designed for South African popula-
tions, collected self-report information from various do-
mains including demographics and social characteristics,
AOD use and need for treatment, and barriers and facili-
tators to AOD treatment. The individual question items
and measures contained in this questionnaire are de-
scribed below.
Use of AOD treatment The criterion variable for this
study was AOD treatment utilization. This was assessed
by the question: “Have you ever received treatment for
AOD problems? “ This item had a “yes” (1) or a “no” (0)
response.
Need for treatment variables Two items “Do you think
you need AOD treatment?” and “Have others suggested
you need AOD treatment” examined internally and exter-
nally perceived need for treatment. These items had a
“yes” (1) or “no” (0) responses.
The “Stages of Change, Readiness and Treatment Eager-
ness Scale” (SOCRATES-8D) measured readiness to
change AOD use; a situational indicator of perceived need
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seven-item “Problem Recognition” scale, the four-item
“Ambivalence” and the eight-item “Taking Steps to
Change” subscale. Each item is rated on a 5-point Likert
scale, with responses ranging from “strongly disagree” (1)
to “strongly agree” (5). The SOCRATES has good con-
struct validity; predicting treatment initiation, treatment
engagement and treatment outcomes [16]. Good internal
reliability coefficients have been reported, with coefficients
ranging from .68 to .89 for the subscales and test-retest re-
liability correlations ranging from .83 to .99 [16,17]. This
study obtained alpha coefficients ranging from .91 to .95
for the subscales.
Predisposing factors The following socio-demographic
variables were included in the analysis: age (with re-
sponses ranging from 18 to 53), gender (male or female),
race (Black African or Coloured), number of years of
education received and neighbourhood disadvantage.
Number of years of education received was treated as a
continuous variable with responses ranging from 0 years
to 15 years for those with completed Bachelor degrees.
Neighbourhood disadvantage was assessed using the
ten-item “Neighbourhood Environment Scale” (NES)
which includes items that examine perceptions of neigh-
bourhood poverty, neighbourhood dilapidation, per-
ceived drug dealing and drug use in the neighbourhood,
and perceptions of neighbourhood safety [18]. Items are
rated on a five-point Likert scale from “strongly dis-
agree” (1) to “strongly agree” (5). This study obtained a
Cronbach alpha coefficient of .82 for the NES.
Enabling and restricting factors A five-item “Afford-
ability barriers scale” [19] measured the extent to which
treatment costs, concerns about loss of income due to
time taken from work, and transport costs hampered
treatment utilization. Items are rated on a five-point Likert
scale; with responses ranging from “a very small extent”
(1) to “a very large extent” (5). Aggregated responses aver-
aged to give a composite score (ranging from 1 to 5), with
higher scores indicating more cost barriers. A Cronbach
alpha coefficient of .84 was obtained for this scale.
“Awareness of AOD treatment services” was examined
through a single-item question that asks participants to
list all known AOD treatment services. Based on re-
sponses to this question, the number of known AOD
treatment facilities is calculated, with larger numbers in-
dicating greater awareness of services. Responses to this
item ranged from 0 known facilities to 8 known services.
“Geographic access to AOD treatment services” was
examined through a single-item question that asks partici-
pants to estimate the amount of time it took (in 15 minute
intervals) to travel to the nearest AOD treatment service.
Responses to this item ranged from one 15-minute intervalto nine 15-minute intervals (representing 135 minutes),
with higher scores on this item reflecting greater geo-
graphic access barriers to treatment.
The 10-item “Stigma Consciousness Scale” was used to
examine internalized stigma related to participants’ AOD
use [20]. More specifically, this scale measures expecta-
tions of being judged negatively on the basis of one’s AOD
use. Item responses range on 10-point Likert scale from
“strongly disagree” (1) to “strongly agree” (10). Responses
are summed and averaged to give a composite stigma con-
sciousness score. Possible composite scores range from 1
to 10, with higher scores reflecting more internalised
stigma. Initial studies obtained a Cronbach alpha coeffi-
cient of .87 for this scale [19]. This study obtained a
Cronbach alpha coefficient of .84 for the scale.
The 10-item “Treatment concerns” scale [19] was used
to measure individual concerns about what happens in
AOD treatment. This scale includes items that explore
fears about the kind of treatment that they might receive,
fears about what might happen to them during treatment,
and fears about the kinds of people they might meet dur-
ing treatment. Item responses range on five-point Likert
scale from “to a very small extent” (1) to “a very large ex-
tent” (5). Aggregated responses are averaged to give an
overall score (ranging from 1 to 5), with higher scores
reflecting greater treatment concerns. This scale has good
internal consistency, with a Cronbach alpha coefficient of
.90 being obtained for the scale.
Data analysis
Bivariate comparisons of the utilization variable and the
predisposing, enabling and need measures were conducted
separately for each race group. Chi-square tests of associ-
ation were conducted on categorical variables by utiliza-
tion and odds ratios (OR) were calculated to measure the
strength of these associations. Independent sample t-tests
were used to compare the utilization groups on continu-
ous variables and point-biserial correlation coefficients
(rpb) were used to measure the strength of these associa-
tions. Following this, multiple logistic regression analyses
were performed to determine which variables were inde-
pendently associated with treatment use. Utilization was
regressed separately for Black African and Coloured par-
ticipants so that the unique profile of variables associated
with utilization could be identified for each group. For
each regression analysis, only the predisposing, enabling
and need variables that were significantly and moderately
associated (OR ≥ 2.5 or rpb ≥ 0.25) with utilization in bi-
variate analyses were entered into the model.
Results
Sample description
The final sample consisted of 434 cases and 555 controls
(N = 989). Chi-square tests of association revealed that
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larly, independent sample t tests showed that the mean
age and level of education did not differ among cases
and controls (Table 1).
Bivariate analyses
Predisposing variables Years of education was signifi-
cantly associated with treatment use for Black African
(t (424) = 2.91; p = 0.004) and Coloured participants
(t (497) = -0.43; p <0.001). While the number of years
of education was negatively correlated with treatment
use for Black African participants (rpb = -0.13), it was
positively associated with treatment use among Coloured
participants (rpb = 0.19); however the effect sizes of these
associations were weak. In addition, age (t (487) = 2.37;
p = 0.018) and NES (t (487) = 5.64; p <0.001) were asso-
ciated with treatment use for Coloured participants
(Table 2). However the effect sizes of these associa-
tions were weak (rpb = -0.11 for age and rpb = -0.25 for
neighbourhood disadvantage).
Need variables The categorical variable “do you think
you need AOD treatment” was significantly associated
with utilization for both race groups (χ2 (1, N = 500) =
53.74, p <0.001 for Black African participants; χ2 (1, N =
489) = 12.47, p <0.001 for Coloured participants). The
odds of utilizing treatment were almost nine-fold greater
for Black African participants (OR = 8.65; CI (95): 4.48-
16.69) and almost two-fold greater for Coloured partici-
pants (OR = 1.92; CI (95): 1.34-2.77) who thought they
needed AOD treatment compared to participants who did
not think they needed treatment. In addition, the categor-
ical variable “Have others suggested you need AOD treat-
ment?” was significantly associated with utilization for
both race groups (χ2 (1, N = 500) = 31.30, p <0.001 for
Black African participants; χ2 (1, N = 489) = 24.71, p <
0.001 for Coloured participants). The odds of entering
treatment were four-fold greater for Black African partici-
pants (OR = 4.27; CI (95): 2.50-7.31) and about three-fold
greater for Coloured participants (OR = 3.43; CI (95):
2.07-5.68) for whom others had suggested the need forTable 1 Demographic information for the overall sample (N =
Variable Cases% (n) Cont
Male 54.4% (236) 50.3%
Female 45.6% (198) 49.7%
Black/African 50.9% (221) 50.3%
Coloured 49.1% (213) 49.7%
Mean age in years (SD)a 24.95 (4.81) 25.43
Mean education - grade (SD) 11.55 (1.57) 11.45
Total (N) 434 555
a SD Standard deviation.AOD treatment, relative to participants for whom others
had not suggested the need for treatment (Table 2).
Significant differences were found between cases and
controls on the SOCRATES-*D scales (Table 2). For both
race groups, the treatment use group reported higher
scores on the “Problem Recognition” scale (t (498) = -10.72,
p <0.001 for Black Africans; t (481) = -7.01, p <0.001 for
Coloureds), “Ambivalence” scale (t (498) = -8.44, p <0.001
for Black Africans; t (487) = -6.45, p <0.001 for Coloureds)
and the “Taking Steps to Change” scale (t (498) = -18.09,
p <0.001 for Black Africans; t (487) = -8.84, p <0.001 for
Coloureds) than the treatment non-use group (Table 2).
All of these scales were moderately associated with treat-
ment use for Coloured and Black African participants
(with rpb coefficients ranging from 0.28-0.43), except for
the “Taking Steps to Change” scale which was strongly
associated (rpb = 0.63) with treatment use among Black
African participants (Table 2).
Enabling/restricting variables For both race groups,
cases obtained significantly higher scores on the “Treat-
ment Concerns” (t (430) = -4.58, p <0.001 for Black African;
t (475) = -4.45, p <0.001 for Coloured participants) and
“Stigma consciousness” scales (t (498) = -7.83, p <0.001 for
Black African; t (487) = -7.53, p <0.001 for Coloured partici-
pants) than controls. The “Stigma consciousness” scale was
moderately associated with utilization for Black African
(rpb = 0.33) and Coloured participants (rpb = 0.25), but the
“Treatment Concerns” scale was weakly associated with
utilization (rpb ranging from 0.20-0.21). Cases reported
significantly fewer geographic access barriers, that is
shorter travelling times to the nearest treatment centre,
(t (498) = 7.39, p <0.001 for Black Africans; t (487) =
11.24, p <0.001 for Coloureds), fewer affordability barriers
(t (498) = 12.92, p <0.001 for Black Africans; t (395) =
18.62, p <0.001 for Coloureds) and greater awareness of
treatment services than controls (t (498) = -34.09, p <
0.001 for Black Africans; t (487) = -16.64, p <0.001 for
Coloureds). These variables were strongly associated with
utilization for both Black African (rpb ranging from 0.50-
0.84) and Coloured participants (rpb ranging from 0.45-989)
rol% (n) Chi-square/ t -test (p) Overall% (n)
(279) 1.65 (0.20) 52.1% (515)
(276) 47.9% (474)
(279) 0.04 (0.84) 50.6% (500)
(276) 49.4% (489)
(5.98) 1.38 (0.17) 25.22 (5.51)
(1.52) −0.95 (0.34) 11.50 (1.54)
- 989
Table 2 Predisposing, need and enabling variables by utilization for each race group
Variables Coloured Black/African
No use controls
(N = 276) Mean (SD)
Treatment
use (N = 213)
Mean (SD)
Effect size
(ORa: 95% CIb/ rpb
c
No use controls
(N = 279) Mean (SD)
Treatment
use (N = 221)
Mean (SD)
Effect size
(OR: 95% CI/ rpb
Predisposing variables
Age 26.22 (5.95) 24.98 (5.54) −0.11* 24.63 (5.92) 24.93 (3.99) 0.03
Education (years) 10.96 (1.51) 11.54 (1.47) 0.19** 11.95 (1.37) 11.55 (1.66) −0.13**
NES 43.77 (3.49) 41.37 (5.86) −0.25** 40.96 (2.71) 41.47 (4.17) 0.07
Need for treatment variables
Think need treatment (n,%) 128 (46.4%) 133 (62.4%) 1.92: 1.34-2.77 192 (68.8%) 210 (95.0%) 8.65: 4.48-16.69
Others think need treatment
(n,%)
195 (70.7%) 190 (89.2%) 3.43:2.07-5.68 199 (71.3%) 202 (91.4%) 4.27:2.50-7.31
SOCRATES- Problem
recognition
21.61 (8.07)) 26.37 (6.94) 0.30*** 22.89 (6.07) 27.86 (3.67) 0.43***
SOCRATES-Ambivalence 12.66 (4.47) 15.06 (3.50) 0.28*** 13.95 (3.20) 16.04 (2.04) 0.35***
SOCRATES- Taking steps 17.57 (5.61) 22.86 (7.61) 0.37*** 17.30 (3.45) 27.20 (8.28) 0.63***
Enabling variables
Treatment concerns scale 28.36 (9.27) 31.61 (6.05) 0.20*** 24.52 (7.29) 27.86 (8.65) 0.21***
Stigma consciousness scale 7.95 (1.51) 8.70 (1.34) 0.25*** 7.30 (1.48) 8.48 (1.88) 0.33***
Awareness of AOD Treatment
(# of known treatment centres)
2.44 (0.99) 3.83 (0.80) 0.60*** 1.65 (0.67) 3.96 (0.86) 0.84***
Geographic access
(Time to treatment)
3.63 (0.59) 2.92 (0.80) −0.45*** 3.70 (0.50) 2.53 (0.64) −0.72***
Affordability barriers 37.71 (6.48) 24.98 (8.19) −0.66*** 39.81 (5.81) 30.73 (9.75) −0.50***
a OR Odds Ratio.
b 95% CI = 95% confidence intervals.
c rpb = point-biserial correlation coefficient.
*p < .05; ** p < .01; *** p < .001.
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never accessed treatment had significantly higher scores
on the “Affordability barriers” scale than their Coloured
counterparts (t (553, N = 555) = 4.03, p < 0.001).
Logistic regression of utilization
Utilization was regressed separately for each race group
while controlling for the potential confounding effect of
gender. Only variables that were at least moderately asso-
ciated with utilization during bivariate analysis were en-
tered into the regression models. Variables entered into
the regression model for Black African participants in-
cluded: Think that need treatment; Others suggesting the
need for treatment; the SOCRATES Problem Recognition,
Ambivalence, and Taking Steps to Change subscales; the
Stigma Consciousness scale; Geographic access (travel
time to treatment); Awareness of AOD treatment services,
and the Affordability barriers scale. Variables entered into
the regression model for Coloured participants included:
the NES, Others suggesting the need for treatment; the
SOCRATES Problem Recognition, Ambivalence, and Tak-
ing Steps to Change subscales; the Stigma Consciousness
scale; Geographic access (travel time to treatment);Awareness of AOD treatment services, and the Affordabil-
ity barriers scale. A test of the full model versus the model
with the intercept only was statistically significant for
Black African participants (χ2 (10; N = 500) = 590.91, p <
0.001) and Coloured participants (χ2 (10; N = 489) =
422.89, p < 0.001). These models accounted for approxi-
mately 69% (Nagelkerke R2 = 0.691) and 58% (Nagelkerke
R2 = 0.579) of the estimated variance in utilization for
Black African and Coloured participants, respectively.
According to the Hosmer and Lemeshow test, the models
were a good fit for the data (χ2 (8; N = 500) = 3.07, p =
0.798 for Black African participants; χ2 (8; N = 489) = 6.52,
p = 0.589 for Coloured participants).
There were no predisposing variables significantly as-
sociated with utilization after statistically adjusting for
the other variables in the models (Table 3). When holding
the predisposing and enabling variables constant, Black
African participants had several need-for-treatment vari-
ables significantly associated with utilization (Table 3).
Specifically, the odds of treatment access increased more
than 13-fold (OR = 13.70; CI (95): 1.44-125.00) for Black
African participants who thought they needed to go for
AOD treatment (compared to those who did not think
Table 3 Summary of multiple logistic regression analyses using predisposing, enabling and need factors as predictors
of substance abuse treatment utilization
Independent variables Coloured participants (N = 489) Black African participants (N =500)
OR a (95% CI)b,c OR (95% CI)d
Predisposing variables
Gender (Male) 0.66 (0.34-1.31) 0.98 (0.21-4.57)
NES (values range from 10-90) 0.99 (0.91-6.61) ———————————————e
Need for treatment variables
Think need treatment (Yes) ———————————————e 13.70 (1.44-125.00)
Others think need treatment (Yes) 1.28 (0.54-3.06) 38.46 (3.98-333.33)
SOCRATES Problem Recognition scale (values range from 7 to 35) 1.04 (0.95-1.13) 0.87 (0.73-1.05)
SOCRATES Ambivalence scale (values range from 4 to 20) 1.04 (0.89-1.23) 1.12 (0.87-1.45)
SOCRATES Taking Steps to Change scale (values range from 8 to 40) 1.05 (0.99-1.12) 1.30 (1.13-1.48)
Enabling/restricting variables
Awareness: # known treatment centres (values range from 0-8) 4.42 (2.96-6.61) 35.50 (11.33-111.25)
Geographic access: Time to treatment in 15 min intervals
(values range from 1-9)
0.49 (0.30-0.81) 0.04 (0.01-0.15)
Affordability barriers scale (values range from 1-5) 0.83 (0.79-0.87) 0.90 (0.83-0.98)
Stigma consciousness scale (values range from 1-10) 2.04 (1.52-2.73) 1.31 (0.89-1.95)
a OR Odds Ratio.
b 95% CI = 95% confidence intervals.
c Model summary: χ2 (10; N = 489) = 422.89, p < 0.001; Nagelkerke R2 = 0.579.
d Model summary: χ2 (10; N = 500) = 590.91, p < 0.001; Nagelkerke R2 = 0.691.
e Variables not entered into the model.
f The bolded odds ratios refer to statistically significant associations.
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38.46; CI (95): 3.98-333.33) for those for whom others had
suggested the need for AOD services relative to those who
did not receive this advice. In addition the SOCRATES
“Taking Steps” scale was significantly associated with ac-
cess for Black African participants; with a one unit in-
crease in scale scores (reflecting greater readiness to
change) increasing the odds of entering AOD treatment
by a multiplicative factor of 1.30 (OR = 1.30; CI (95): 1.13-
1.48). There were no treatment need variables significantly
associated with treatment use among Coloured partici-
pants (Table 3).
Several enabling variables were significantly and strongly
associated with utilization for Black African and Coloured
participants (Table 3). Awareness of services was positively
associated with utilization for both groups. For every add-
itional treatment centre that Black African or Coloured
participants knew of, the odds of utilizing treatment in-
creased by a multiplicative factor of 35.50 (OR = 35.50; CI
(95): 11.33-111.25) and 4.42 (OR = 4.42; CI (95): 2.96-
6.61), respectively. Geographic access was also associated
with utilization for both races. For every 15 minute in-
crease in travelling time to treatment, the odds of
accessing treatment were reduced by 51% for Coloured
(OR = 0.49; CI (95): 0.30-0.81) and 96% (OR = 0.04; CI
(95): 0.01-0.15) for Black African participants. Affordabil-
ity barriers also were significant partial predictors ofutilization for both races, with every one unit increase in
the affordability barriers scale reducing the odds of access-
ing treatment by 17% for Coloured (OR = 0.83; CI (95):
0.79-0.87) and 10% (OR = 0.90; CI (95): 0.83-0.98) for
Black African participants.
One other enabling variable, stigma consciousness, was
significantly associated with treatment utilization for
Coloured participants only. Among Coloured participants,
every one unit increase in the Stigma Consciousness scale
doubled the odds of accessing treatment (OR = 2.04; CI
(95): 1.52-2.73; Table 3).
Discussion
Previous studies have identified racial disparities in the
use of AOD treatment services in South Africa, with
Black African and Coloured persons consistently under-
represented in speciality AOD treatment services [5,21].
However there has been a paucity of research examining
the factors that underpin these racial disparities. To the
best of our knowledge, this study is the first to examine
the unique profile of barriers to AOD treatment use
among Black African and Coloured persons. As such,
findings from this study potentially deepen current un-
derstandings of how racial disparities in access to AOD
treatment can be ameliorated and service coverage ex-
panded to include these underserved populations. More
specifically, the study found several similarities and
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experienced by Black African and Coloured AOD-using
persons.
First, findings suggest that key structural barriers to
accessing AOD treatment are common among people
disadvantaged during the apartheid regime, irrespective
of race group membership. More specifically, geographic
access barriers (related to length of time taken to travel
to the nearest treatment facility) and affordability bar-
riers were significantly associated with not accessing
AOD treatment for both Black African and Coloured
participants. These findings are not altogether surprising
given that several studies have noted similar structural
barriers to accessing public health services in post-
apartheid South Africa for Black African and Coloured
South Africans [6,8,22]. Although these key barriers
were reported by Black African and Coloured persons,
variations in the extent to which these barriers impact
on the probability of AOD treatment use were noted.
Specifically Black African persons appear more suscep-
tible to the effects of geographic access barriers than
Coloured persons. This may be the result of the endur-
ing spatial inequalities that exist between race groups in
the country. During apartheid both Black African and
Coloured South Africans were forced to reside in areas
that were geographically removed from urban hubs,
however apartheid planning ensured that Black African
communities were relatively further removed from these
well-resourced urban centres and had relatively less in-
frastructure than Coloured communities [6,8]. This in-
creased the distance and time required to travel to the
nearest treatment facility. Unfortunately, this spatial seg-
regation did not stop with the end of apartheid, with
post-apartheid low-cost housing developments for Black
African communities who previously had little access to
social housing still located far from the urban periphery
[23]. In addition, these areas are poorly served by public
transport, with Black African populations having signifi-
cantly less access to public transport services than
Coloured populations [23]. Together these factors most
likely underpin Black African persons’ increased vulner-
ability to geographic access barriers through increasing
the distance, time and difficulty in travelling to the
nearest AOD treatment facility.
These findings suggest several strategies for improving
access to AOD treatment for Black African and Coloured
persons (although Black African persons may benefit most
from interventions to reduce geographic barriers to treat-
ment entry). First, careful consideration should be given to
the positioning of new AOD treatment services and how
these services are delivered. If new services are located far
from Black African communities they will entrench geo-
graphic access barriers for this population. In addition to
building new facilities close to underserved communities,another strategy would be to introduce mobile outpatient
AOD services into underserved communities. Not only
would mobile services improve treatment availability, but
they would reduce Black African persons’ travel time (and
concomitant costs) to the nearest AOD service. As mobile
services have never been used for the delivery of AOD ser-
vices in South Africa, future research should consider
piloting a mobile AOD service to test whether this mode
of service delivery is feasible to implement and acceptable
to the target population.
In addition, findings suggest that affordability barriers
are somewhat stronger determinants of AOD treatment
access for poor Coloured persons compared to their Black
African counterparts. This finding is counterintuitive
given evidence that Black African communities experience
more financial barriers to accessing health services than
Coloured communities [9,23]. This surprising finding does
not mean that affordability barriers are not significant de-
terminants of AOD treatment access for Black African
persons. A closer examination of the data shows that
Black African persons who had never accessed treatment
reported significantly more affordability concerns com-
pared to their Coloured counterparts. It is possible that
the relatively homogenous responses of Black African par-
ticipants on the affordability barriers scale compared to
Coloured participants may have reduced the possibility of
detecting any measurable association between these bar-
rier variables and access for this population subgroup in
multivariate analyses. Regardless of the reason for these
differences, findings point to the importance of reducing
treatment costs as a means to improve AOD treatment
use for both Black African and Coloured communities. In
South Africa, AOD treatment services are only offered by
stand-alone treatment facilities. There are few free AOD
treatment services available and most not-for -profit ser-
vices require user co-payment fees [21]. One strategy for
expanding the availability of free AOD services to poor
South African communities would be to initiate AOD
intervention services within the country’s free primary
health care and social service systems. As these primary
health and social services are located within easy reach of
underserved communities, the provision of AOD services
within these settings would alleviate the financial burden
of user co-payment fees while also reducing geographic
barriers to AOD treatment access.
A shared facilitator to AOD treatment entry for Black
African and Coloured persons is awareness of where to
go for AOD treatment, with the likelihood of AOD
treatment use improving with every increase in the
number of known treatment facilities. This suggests that
access for underserved groups could be improved by in-
creasing public awareness of where and how to access
AOD treatment. However, we found differences in the
degree to which Black African and Coloured persons
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Black Africans relatively more susceptible to the effects
of awareness on access than Coloured persons. This
could be because of poor health literacy around AOD-
related problems and addiction in Black African com-
munities relative to Coloured communities. In recent
years, Coloured communities have been the target of
several AOD awareness campaigns whereas Black African
communities have been relatively neglected due to the
perceived low prevalence of AOD problems in these com-
munities [24].
One promising avenue for improving awareness of
AOD services (and subsequently treatment use) among
Black African communities lies in the important role
that relationships with others play in Black African com-
munities. Black African communities have a collectivist
cultural orientation that emphasises relatedness to and
interdependence with others [25,26]. In comparison,
Coloured communities are not as collectivist in cultural
orientation and place less emphasis on relatedness to
others [25]. Within Black African communities, this em-
phasis on social and community relatedness impacts on
the use of health services; with evidence of social net-
works in these communities buffering people against the
effects of limited awareness and poor health literacy on
service use [26,27]. Awareness-related interventions
targeted at the level of the social network thus may be
an effective strategy for improving access to AOD treat-
ment in Black African communities. This study’s finding
of considerably greater odds of accessing treatment
among Black African participants for whom significant
others had suggested the need for AOD treatment (com-
pared to those for whom significant others had not) pro-
vides support for the potential role that social networks
can play in facilitating treatment access in Black African
communities. Community health workers (that is health
workers without formal health care training who func-
tion to promote community health, provide preventive
services, and address barriers to health care [28]) are
ideally placed to conduct community outreach to im-
prove awareness of AOD treatment and to provide sup-
port for families and social networks dealing with AOD
problems. With a little investment in training, this cadre
of health worker could also help identify and encourage
people with AOD problems to seek services.
Further distinctions in the profile of factors associated
with AOD treatment use among Black African and
Coloured persons were found. Perceived need for treat-
ment (as assessed by the question do you think you need
treatment) and the SOCRATES “taking steps to change”
scale were associated with AOD treatment entry for
Black African participants only. These findings show
that Black African participants are most likely to enter
treatment when they have a strong perceived need fortreatment and are already taking steps to change their
AOD use. In contrast, these variables were not associ-
ated with access to AOD treatment for Coloured partici-
pants, suggesting that Coloured persons are able to
access treatment regardless of their degree of problem
recognition or readiness to change. These findings imply
that Black African persons enter AOD treatment at a
later point than Coloured persons, when their AOD
problems are apparent and they identify the importance
of change. This may be a result of greater difficulties in
accessing AOD treatment relative to their Coloured
counterparts.
A further variation between Black African and Coloured
AOD treatment seekers was that perceived stigma was sig-
nificantly (and positively) associated with AOD treatment
use among Coloured participants only. This finding of a
positive association between stigma and treatment use is
surprising given previous research which notes that stigma
hinders rather than promotes entry into AOD treatment
[29]. One possible explanation for this unexpected finding
lies in this study’s measurement of perceived stigma. This
study employed the stigma consciousness scale which
measures perceptions of being judged negatively on the
basis of one’s AOD use rather than on the basis of one’s
use of AOD treatment services [20]. It is quite possible
that high levels of stigma around problematic AOD use
cause such distress that people enter treatment partly to
alleviate this distress. Earlier qualitative research which
reported that people from disadvantaged communities
experience stigma in relation to their problematic AOD
use rather than their use of AOD services [30] provides
some support for this explanation. Further, this qualita-
tive research pointed to the intense stigma associated
with the problematic use of methamphetamine. As
methamphetamine-related problems are significantly
more prevalent among Coloured relative to Black African
communities [5], this may help explain why perceived
stigma was such a salient facilitator of AOD treatment
entry for Coloured participants but not for Black African
participants.
Findings from this study should be considered in the
light of several limitations. As a case-control design pre-
cludes a temporal examination of the factors associated
with treatment utilization, inferences about causality
cannot be made. Further, the use of a matched design
ruled out an examination of race differences in the likeli-
hood of AOD treatment use. Third, the crude conceptu-
alisation of access employed by this study prevented an
examination of whether there were differences between
participants who had unsuccessfully attempted and those
who had never attempted to access services. Fourth,
strict selection criteria may have reduced the variability
of the sample and impacted on the extent to which many
predisposing variables were associated with treatment
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advantaged communities in Cape Town, the extent to
which findings are representative of more rural or other
urban regions in South Africa is questionable. Yet as the
Western Cape is one of the best resourced provinces in
terms of AOD services [21], it is highly likely that these
barriers are even more salient elsewhere in the country.
These limitations highlight the need for further re-
search on AOD treatment use in South Africa. Future
research should include longitudinal prospective studies
that track people with AOD-related difficulties and allow
researchers to unpack the factors that precipitate entry
into AOD treatment utilization for each race group.
These longitudinal studies will also allow researchers to
monitor racial disparities in accessing treatment and
evaluate the impact of interventions to reduce these dis-
parities. To address concerns about the external validity
of findings, studies on factors associated with AOD
treatment use in other parts of the country (particularly
rural regions) and for other population subgroups (such
as adolescents) are required. In addition, researchers
should conduct experimental intervention studies that
test whether study recommendations for improving ac-
cess to AOD treatment among poor Black African and
Coloured South Africans impact positively on AOD
treatment use.
Conclusion
Despite some limitations this study provides evidence of
differences in barriers to AOD treatment use among
poor Black African and Coloured South Africans; with
Black Africans appearing more vulnerable to the effects
of geographic access and awareness barriers and entering
treatment at a later point than their Coloured counter-
parts. Findings suggest several strategies for improving
access for these underserved groups. First, to avoid
entrenching geographic barriers, new AOD services
should be placed in locations easily accessible by public
transport and in communities with high service needs
and poor service coverage. Second, mobile AOD services
may offer an efficient solution to affordability and geo-
graphic access barriers by reducing the infrastructure
costs of new facilities and allowing services to be moved
between and within communities. Third, if AOD inter-
vention services are provided within the primary health
and social service system this would reduce affordability
and geographic access barriers while expanding the
availability of care. Finally, service providers should con-
sider using community health workers to conduct out-
reach in order to improve awareness of AOD treatment
within Black African communities. Through increasing
community awareness of when, where and how to access
services, outreach workers can positively impact on Black
African South Africans’ use of AOD treatment services.Abbreviations
AOD: Alcohol and other drug.
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